Beam Therapeutics upgraded to Outperform from Market Perform at Leerink

TipRanks11-07

Leerink upgraded Beam Therapeutics (BEAM) to Outperform from Market Perform with a price target of $39, up from $27. The firm notes that prior to Tuesday’s BEAM-101 data in sickle-cell disease, risk ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481072908?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/4SmA9KoGNomql4gwxNxdZw--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/ce0712556f8b4e54fa2af52107a5b0b6","is_english":true,"pubTime":"2024-11-07 19:26","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2481072908","market":"us","top_or_hot":-1,"title":"Beam Therapeutics upgraded to Outperform from Market Perform at Leerink","media":"TipRanks","content":"<div>\n<p>Leerink upgraded Beam Therapeutics (BEAM) to Outperform from Market Perform with a price target of $39, up from $27. The firm notes that prior to Tuesday’s BEAM-101 data in sickle-cell disease, risk ...</p>\n\n<a href=\"https://finance.yahoo.com/news/beam-therapeutics-upgraded-outperform-market-112614153.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Beam Therapeutics upgraded to Outperform from Market Perform at Leerink</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeam Therapeutics upgraded to Outperform from Market Perform at Leerink\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-07 19:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/beam-therapeutics-upgraded-outperform-market-112614153.html><strong>TipRanks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Leerink upgraded Beam Therapeutics (BEAM) to Outperform from Market Perform with a price target of $39, up from $27. The firm notes that prior to Tuesday’s BEAM-101 data in sickle-cell disease, risk ...</p>\n\n<a href=\"https://finance.yahoo.com/news/beam-therapeutics-upgraded-outperform-market-112614153.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"https://finance.yahoo.com/news/beam-therapeutics-upgraded-outperform-market-112614153.html","article_id":"2481072908","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/4SmA9KoGNomql4gwxNxdZw--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/ce0712556f8b4e54fa2af52107a5b0b6"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/beam-therapeutics-upgraded-outperform-market-112614153.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2481072908","pubTimestamp":1730978774,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Leerink upgraded Beam Therapeutics  to Outperform from Market Perform with a price target of $39, up from $27. The firm notes that prior to Tuesday’s BEAM-101 data in sickle-cell disease, risk of a safety signal kept Leerink on the sidelines. Following disclosure of a patient death, shares opened down over 10%, but recovered over the day, as focus shifted to BEAM-301 data in alpha-1 antitrypsin deficiency, where the firm sees a far more attractive risk/reward. Leerink takes this opportunity to step back in positively after a period of uninspiring stock performance given strong product/market-fit for in vivo single-point mutation base editing in AATD, and potential to address both lung and liver manifestations.Beam Therapeutics Reports Steady Progress in Q3 2024. Cathie Wood’s ARK Investment buys 162.5K shares of Beam Therapeutics today. Beam could see significant upside over next 6-12 months, says Wedbush. Beam Therapeutics to present data on BEAM-101, BEAM-201 at ASH meeting","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"LENZ":"Therapeutics","BEAM":"Beam Therapeutics, Inc."},"translate_title":"Leerink将Beam Therapeutics从市场表现上调至跑赢大盘","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"BEAM":0.9},"content_text":"Leerink upgraded Beam Therapeutics (BEAM) to Outperform from Market Perform with a price target of $39, up from $27. The firm notes that prior to Tuesday’s BEAM-101 data in sickle-cell disease, risk of a safety signal kept Leerink on the sidelines. Following disclosure of a patient death, shares opened down over 10%, but recovered over the day, as focus shifted to BEAM-301 data in alpha-1 antitrypsin deficiency, where the firm sees a far more attractive risk/reward. Leerink takes this opportunity to step back in positively after a period of uninspiring stock performance given strong product/market-fit for in vivo single-point mutation base editing in AATD, and potential to address both lung and liver manifestations.\n\nPublished first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>\n\n\nSee today’s best-performing stocks on TipRanks >>\n\n\nRead More on BEAM:\n\nBeam Therapeutics Reports Steady Progress in Q3 2024\nCathie Wood’s ARK Investment buys 162.5K shares of Beam Therapeutics today\nBeam could see significant upside over next 6-12 months, says Wedbush\nBeam says patient death determined by investigator to be unrelated to BEAM-101\nBeam Therapeutics to present data on BEAM-101, BEAM-201 at ASH meeting","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481072908"}